Allergy Thera. Share News (AGY)

Allergy Thera. Information

Buy AGY Shares
Add AGY to Watchlist
Add AGY to Alert

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 4.05

Bid: 3.80

Ask: 4.30

Change: 0.15 (3.85%)

Spread: 0.50 (13.158%)

Open: 3.90

High: 4.05

Low: 3.72

Prev. Close: 3.90

Last checked at -

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

Wed, 13th Dec 2023 09:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Impellam Group PLC, up 26% at 819.12 pence, 12-month range 580.00p-950.00p. Shares in the staffing firm rise, though back off from new 52-week high, after it says it has agreed to a GBP483.2 million takeover offer from Heather Global PLC, a bidding vehicle for HeadFirst Global BV. The HeadFirst offer values each Impellam share at 1,084.4 pence in total. This represents a 67% premium over the stock's 650.00p close in London on Tuesday. The offer is supported by Impellam's majority owner Michael Ashcroft, a UK businessman who was formerly deputy chair of the UK Conservative Party.

----------

Allergy Therapeutics PLC, up 9.5% at 2.13p, 12-month range 0.37p-5.64p. The biotechnology firm, focused on allergy vaccines, updates on G306 Phase III trial of Grass MATA MPL, its short-course subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. It notes "highly significant secondary efficacy endpoints with an acceptable safety and tolerability profile observed for Grass MATA MPL." Chief Executive Manuel Llobet says: "We are very pleased that the primary and secondary endpoints from this trial strongly align, and all data analysed demonstrate the beneficial effect of our Grass MATA MPL product. These data, alongside the results from our earlier G309 field study, provide a strong, significant and consistent data package for our discussions with relevant health authorities."

----------

AIM - LOSERS

----------

Future Metals NL, down 12% at 1.30p, 12-month range 1.13p-6.40p. The West Perth-based exploration company focused on the Panton platinum group metals project in Western Australia says its shares have been suspended on the Australian Securities Exchange in Sydney pending the release of an announcement in relation to a "potential capital raising". The company's shares continue to trade as normal on AIM in London.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

More News

28 Mar 2011 14:57

London afternoon: Shares mark time

Footsie finished the morning clinging on to positive territory and not much changed over the lunch time trading session, with a mildly firmer start on Wall Street providing little additional impetus. Worries that Japanese carmakers may have to suspend production at their plants in China following t

28 Mar 2011 14:06

Weak German market hits sales at Allergy Therapeutics

Pharmaceutical firm Allergy Therapeutics reported broadly flat revenues and profits for the six months ended 31 December, as a result of weakness in its core German market. First half revenue was £27.4m, slightly higher than £27.3m in 2009. Weakness in the euro also had a £1.1m impact on turnover.

20 Sep 2010 14:41

Small caps: Allergy Therapeutics, Goldplat, Avacta

Hay fever treatment specialist Allergy Therapeutics posted an operating profit for the year to June of £1.5m (2009: loss £5.1m) and cut losses to £116,000 from £11.4m. "On the regulatory front, the submission in March 2009 of Pollinex Quattro Grass, our ultra-short course four injection grass alle

22 Jul 2010 12:36

Allergy Therapeutics Sees FY Revenue GBP40.7M, Operating Profit

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN), a specialist pharmaceutical company focused on allergy vaccination, said Thursday, it expects to report revenue of GBP40.7 million, and an operating profit, for the year ended June 30, adding that the results was in-line with current market expe

1 Jul 2010 16:00

UK SMALLCAP ROUNDUP: Wills & Co Declared In Default

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps WILLS & CO STOCKBROKERS LTD, a small cap share dealer, has been declared to be in default by the Financial Services Compensation Scheme, four months afte

1 Jul 2010 12:57

UPDATE: Allergy Therapeutics Buys Swiss Co In Europe Push

(Adds analyst comment, detail.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Allergy Therapeutics PLC (AGY.LN) Thursday said it agreed to buy its Swiss distributor, in one of its first steps in a new strategy to bolster its position in Europe. Allergy sa

1 Jul 2010 10:17

Allergy Therapeutics Buys Teomed For GBP700,000

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN) said Thursday it has agreed to acquire Teomed AG of Switzerland for a consideration of GBP700,000. MAIN FACTS: -The consideration for the acquisition of Teomed will comprise an initial cash payment of GBP500,000 on signing and a deferred

1 Jul 2010 10:04

Allergy Therapeutics Acquisition

TIDMAGY RNS Number : 6201O Allergy Therapeutics PLC 01 July 2010 ? Thursday 1 July 2010 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Allergy Therapeutics to acquire Teomed AG Expands Eur

24 Mar 2010 16:49

Cairn boss raises nearly £3m

Cairn Energy chief executive Sir Bill Gammell has raised nearly £3m from a share sale. Sir Bill sold 721,042 shares in the oil and gas producer and explorer at 414.4p each. He retains 3.21m shares, which is equivalent to 0.23% of the company's share capital. There have been two other sales by Si

1 Mar 2010 11:04

Small caps round-up: Beowulf, E2V, Mobile Doctors...

Beowulf, owner of several exploration projects in Sweden, continues to believe in the commercial prospects for its asset portfolio which has increased in both quantity and quality as well as resource type. Losses grew to £520,000 in 2009 from £399,000 the year before, but it says future price tren

22 Sep 2009 06:47

Tuesday tips round-up: Alliance Trust, MP Evans, Allergy Therapeutics

Alliance Trust's investment stance means that it is always in danger of trailing more heavily geared rivals when the stock market runs sharply ahead. However, on a rolling total return basis it continues to fare well ? ranked first out of its six largest peers over both one and two years. Further,

21 Sep 2009 08:04

Allergy Therapeutics narrows interim loss

Allergy vaccination group Allergy Therapeutics narrowed half year losses and said it is well placed to capitalise on the investments of the past. Pre-tax losses narrowed to £11.44m in the six month ended 30 June compared with a loss of £20.24m last time. Revenues increased by 22% to £37.8m, on a

9 Jul 2009 08:17

Small caps round-up: MBL, Netplay, Playtech...

Big profits and a maiden dividend have sent entertainment products distributor MBL charging higher Thursday. The supplier of CDs, DVDS and games reported a 42% hike in pre-tax profit for the year ended 31 March 2009 to £8.1m on revenue up 77.5% to £143.6m. Its major competitor, Entertainment UK, t

8 Jul 2009 16:52

Booker directors cash in

A number of directors at Booker have sold millions worth of shares the same day as the cash and carry group said profits and net debt remain in line with expectations. Finance director Jonathan Prentis and operating director Bryn Satherley each made £2.63m, selling 7.5m shares at 35.00p. Commercia

12 Jun 2009 07:31

Consortium takes 50% of Allergy

A Latin American business group is to take control of hay fever treatment developer Allergy Therapeutics through the injection of £12.5m of new funds at 12p per share. Azure Ventures, an investment vehicle of the Weinstein family of Chile, whose interests include a group of pharmaceutical companies

Latest Share Chat

Allergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

Login to your account

Quickpicks are a member only feature

Login to your account